Advanced in Dyserythropoietic Anemia and Thrombocytopenia

Maria R. Esposito

Via Marzolo 9, 
Padova, IT 
Advanced in Dyserythropoietic Anemia and Thrombocytopenia
Via Marzolo 9, 
Padova, IT 
OverviewLocationsClinical Research

Overview

Maria Esposito practices in Padova, Italy. Ms. Esposito is rated as an Advanced expert by MediFind in the treatment of Dyserythropoietic Anemia and Thrombocytopenia. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Dyserythropoietic Anemia and Thrombocytopenia, and Gliomatosis Cerebri.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Dyserythropoietic Anemia and Thrombocytopenia.

Gender
Female

Locations

Via Marzolo 9, Padova, 35131, Italy
Other Locations
Naples, Italy
Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Enrollment Status: Completed
Publish Date: April 18, 2025
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
View 1 Less Clinical Trial

34 Total Publications

Cytotoxic effects induced by combined exposure to the mycotoxins sterigmatocystin, ochratoxin A and patulin on human tumour and healthy 3D spheroids.
Cytotoxic effects induced by combined exposure to the mycotoxins sterigmatocystin, ochratoxin A and patulin on human tumour and healthy 3D spheroids.
Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
Published: May 09, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Esposito's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile